🔎 Trials Near Me

Início › Câncer de Ovário › Wisconsin

Ensaios clínicos de Câncer de Ovário em Wisconsin

29 estudos para Câncer de Ovário estão buscando participantes em locais em Wisconsin.

Cidades em Wisconsin

Texto oficial do estudo (Inglês)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • ThedaCare Regional Cancer Center, Appleton
  • ThedaCare Regional Medical Center - Appleton, Appleton
  • Duluth Clinic Ashland, Ashland
  • e mais 42
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05564377

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • University of Wisconsin Carbone Cancer Center, Madison
RecrutandoFase 1/2
Idades 12 e acima · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT04585750

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

  • Research Site, Milwaukee
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 29 de set. de 2026 · NCT05877599

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Mayo Clinic Health System - Northwest Wisconsin, Eau Claire
  • Mayo Clinic Health System - Southwest Wisconsin, La Crosse
RecrutandoEstudo observacional
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05051722

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Madison
RecrutandoFase 2
Idades de 18 a 130 · Todos os sexos · Atualizado em 23 de set. de 2026 · NCT05489211

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213804

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

  • University of Wisconsin - Carbone Cancer Center, Madison
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 22 de set. de 2026 · NCT07213791

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • Froedtert & MCW Cancer Center, Milwaukee
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07109726

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

  • Froedtert and The Medical College of Wisconsin, Milwaukee
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 15 de set. de 2026 · NCT06915025

A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Froedtert & the Medical College of Wisconsin, Milwaukee
RecrutandoFase 2
Idades de 18 a 99 · Mulheres · Atualizado em 15 de set. de 2026 · NCT07023627

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  • Prohealth Care, Waukesha
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 15 de set. de 2026 · NCT07214779

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • University of Wisconsin, Madison
  • Medical College of Wisconsin, Milwaukee
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 14 de set. de 2026 · NCT06787612

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

  • ThedaCare Regional Cancer Center, Appleton
RecrutandoEstudo observacional
Idades 18 e acima · Todos os sexos · Atualizado em 14 de set. de 2026 · NCT05059444

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Zablocki Veterans Administration Medical Center, Milwaukee
RecrutandoVoluntários saudáveis bem-vindos
Idades de 45 a 75 · Todos os sexos · Atualizado em 2 de set. de 2026 · NCT06995898

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

  • Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 27 de ago. de 2026 · NCT06582017

Cognitive Impact of Neoadjuvant Chemotherapy for Gynecologic Cancers

  • UW Carbone Cancer Center, Madison
RecrutandoEstudo observacional
Idades 18 e acima · Mulheres · Atualizado em 27 de ago. de 2026 · NCT07125209

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
  • University of Wisconsin Carbone Cancer Center - University Hospital, Madison
  • Marshfield Medical Center-Marshfield, Marshfield
  • e mais 6
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT07001748

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • Aurora Saint Luke's South Shore, Cudahy
  • Aurora Health Care Germantown Health Center, Germantown
  • e mais 20
Recrutando
Idades de 35 a 50 · Mulheres · Atualizado em 7 de ago. de 2026 · NCT04251052

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • Duluth Clinic Ashland, Ashland
  • Northwest Wisconsin Cancer Center, Ashland
  • Aurora Cancer Care-Southern Lakes VLCC, Burlington
  • e mais 33
RecrutandoFase 3
Idades 18 e acima · Todos os sexos · Atualizado em 7 de ago. de 2026 · NCT06580314

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • Froedtert and the Medical College of Wisconsin, Milwaukee
RecrutandoFase 2/3
Idades 18 e acima · Todos os sexos · Atualizado em 28 de jul. de 2026 · NCT06161025

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

  • 121, Milwaukee
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 16 de jul. de 2026 · NCT06906341

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

  • University of Wisconsin - Carbone Cancer Center - University Hospital, Madison
RecrutandoFase 2
Idades de 18 a 100 · Mulheres · Atualizado em 13 de jul. de 2026 · NCT05887609

Lead-212 PSV359 Therapy for Patients With Solid Tumors

  • University of Wisconsin, Madison
RecrutandoFase 1/2
Idades de 18 a 90 · Todos os sexos · Atualizado em 6 de jul. de 2026 · NCT06710756

Integrated Cancer Repository for Cancer Research

  • Bellin Memorial Hospital, Green Bay
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

  • University of Wisconsin Carbone Cancer Center, Madison
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 24 de jun. de 2026 · NCT05568680

Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer

  • Froedtert Memorial Lutheran Hospital & Medical College of Wisconsin, Milwaukee
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 16 de abr. de 2026 · NCT05659381

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Milwaukee
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.